Stemline Therapeutics

Cancer tumour
#Collaboration #Georgiamune #Immunotherapy #Menarini #Solid tumours #Stemline Therapeutics

Menarini and Georgiamune sign deal for oral immunotherapy

The Menarini Group and Stemline Therapeutics, a wholly-owned subsidiary of the Menarini Group, have announced an exclusive worldwide license and collaboration agreement with Georgiamune for GIM-621.  GIM-621 is a preclinical-stage first-in-class oral small molecule immunotherapy with potential application across multiple solid tumours.   It is one of multiple therapeutic candidates generated… Read More

#Business & Investment #Cancer Research #News

Cancer cells
#Breast cancer #Cancer research #FDA #Gene mutation #Genetics / genomics #Menarini #Oncology #Stemline Therapeutics

FDA-approved therapy targets ESR1 mutations in breast cancer

The first and only treatment specifically indicated for patients with ESR1 mutations in ER+, HER2- advanced or metastatic breast cancer has been approved in the US.  The Food and Drug Administration (FDA) has approved Orserdu (elacestrant) for the treatment of postmenopausal women or adult men, with ER+, HER2-, ESR1-mutated advanced… Read More

#News #Regulatory